Blunt Business

This week we explore the dual impact of cannabis legalisation and rescheduling—focusing on both the massive financial implications for the industry and emerging scientific research on health benefits.The $2 Billion Tax Windfall The program leads with a deep dive into the potential rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act. Experts estimate that rescheduling could result in a $2.3 billion tax break, allowing businesses to finally show healthy profit margins, attract traditional investors, and move away from high-risk private capital.Cannabis as a Tool in the Opioid Crisis The discussion then shifts to a significant study from the Boston University School of Public Health. Research indicates that in states where adult-use cannabis is legal, daily opioid use among people who inject drugs fell by 9 to 11 percentage points.Brain Benefits for Older Adults Finally, the episode highlights surprising new research from the University of Colorado regarding cannabis use